Abstract
Aim:
To evaluate the in vivo antitumor effects of Cantide and the combined effect with 5-fluorouracil.
Methods:
An in situ human hepatocellular carcinoma model was established in mice livers orthotopically. Drugs were administered intravenously and tumor sizes were monitored with calipers. Plasma alpha-fetoprotein (AFP) were detected by radiation immunoassay. Morphology of tumors was evaluated by hematoxylin-eosin (H&E) staining of histological sections. Human telomerase reverse transcriptase (hTERT) protein levels were detected by Western blotting.
Results:
Cantide significantly inhibit in situ human hepatocellular carcinoma growth in mice with a 75 and 50 mg·kg-1·d-1 administration of Cantide compared to the saline group in a dose-dependent manner, which included injecting Cantide 25 mg·kg-1·d-1-VS mg·kg-1·d-1 by iv for 20 d after surgically removing the tumor in liver. Cantide was also found to prevent tumor recurrence in the liver and metastasis in the lung, showing a dose-dependent response. When Cantide was administered by iv combined with 5-fluorouracil, it resulted in a significant reduction in tumor growth compared to either agent alone treatment group. After the treatment with Cantide alone or combined with 5-fluorouracil, plasma AFP concentration decreased in a dose-dependent manner.
Conclusion:
These results demonstrated that Cantide was an effective antitumor antisense oligonucleotide in vivo and has the potential to be developed into a clinical anti-cancer drug.
Similar content being viewed by others
Article PDF
References
Holt SE, Shay JW . Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999; 180: 10–8.
Shen ZY, Xu LY, Li EM, Cai WJ, Chen MH, Shen J, et al. Telom-ere and telomerase in the initial stage of immortalization of esophageal epithelial cell. World J Gastroenterol 2002; 8: 357–62.
Granger MP, Wright W, Shay JW . Telomerase in cancer and aging. Crit Rev Oncol Hematol 2002; 41: 29–40.
Shay JW, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787–91.
Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR . Inhibition of human telomerase activity by peptide nucleic acids. Nat Biol 1996; 14: 615–9.
Zhang RG, Wang XW, Yuan JH, Xie H . Human hepatoma cell telomerase activity inhibition and cell cycle modulation by its RNA component antisense oligodeoxyribonucleotides. Acta Pharmacol Sin 2000; 21: 742–6.
Bennett CF, Cowsert LM . Application of antisense oligonucleotides for gene functionalization and target validation. Curr Opin Mol Ther 1999; 1: 359–71.
Banerjee D . Technology evaluation: G-3139. Curr Opin Mol Ther 1999; 1: 404–408.
Counter CM, Meyerson M, Eaton EN, Euisen LW, Caddle SD, Haber DA, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16: 1217–22.
Yang Y, Chen Y, Zhang C, Huang H, Weissman SM . Nucleolar localization of hTERT protein is associated with telomerase function. Exp Cell Res 2002, 277: 201–9.
Pang JX, Cheng XY, Xu W, Wu SG . Antisense Sp1 oligodeoxy-nucleotide decreases telomerase activity by inhibiting hTERT mRNA expression in Jurkat T cells. Acta Pharmacol Sin 2003; 24: 91–6.
Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 2003; 3794: 3794–800.
Wang SQ, Lin L, Chen ZB, Lin RX, Chen SH, Guan W, et al. Effect of antisense oligonucleotides targeting telomerase catalytic subunit on tumor cell proliferation in vitro. Chin Sci Bull 2002; 47: 993–7.
Nguyen MH and Keeffe EB . Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35: 586–91.
Du QY, Wang XB, Chen XJ, Zhang W, Wang SQ . Antitumor mechanism of antisense Cantide targeting human telomerase reverse transcriptase. World J Gastroenterol 2003; 9: 2030–5.
Hu YP, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Respondent 2003; 9: 2826–36.
Daniel E, Menezes L, Mayer LD . Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol 2002; 49: 57–68.
Pastorino F, Brignole C, Marimpietri D, Paolo D, Zancolli M, Pagnan G, et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 2003; 9: 4595–605.
Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M, et al. Alpha-fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 2002; 35: 853–60.
He P, Tang ZY, Ye SL, Liu BB . Relationship between expression of alpha-fetoprotein messenger RNA and some clinical parameters of human hepatocellular carcinoma. World J Gastro enterol 1999; 5: 111–5.
Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Lopez-Berestein G, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000; 95: 3929–39.
Luger SM, O'Brien SG, Ratajczak J, Ratajczak MZ, Mick R, Stadtmauer EA, et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 2002; 99: 1150–8.
Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002; 8: 3276–84.
Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R, et al. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the R I alpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 1999; 96: 13989–94.
Zhang Y, He DM . Effect of antisense hTERT mRNA oligodeoxynucleotide on telomerase activity of leukemic cells. Cell Biol Int 2002; 26: 427–31.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National High Technology Program of China (No 2004AA-215150).
Rights and permissions
About this article
Cite this article
Lin, Rx., Tuo, Cw., Lü, Qj. et al. Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin 26, 762–768 (2005). https://doi.org/10.1111/j.1745-7254.2005.00762.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00762.x
Keywords
This article is cited by
-
Hepatocellular carcinoma: insight from animal models
Nature Reviews Gastroenterology & Hepatology (2012)